PharmaCyte Biotech, Inc. 10-Q

Item 5. Other Information . None. 37 Item 6. Exhibits. Exhibit No. Description Location 1.1 Underwriting Agreement, dated as of August 9, 2021 Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021. 3.1 Articles of Incorporation of the Company, as amended, dated October 31, 2019 Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed with the SEC on March 13, 2020. 3.2 Certificate of Amendment dated July 2, 2021, to Articles of Incorporation of the Company Incorporated by reference from the Company’s Current Report on Form 8-K filed on July 6, 2021 3.3 Certificate of Change to Articles of Incorporation of the Company, dated July 9, 2021 Incorporated by reference to from the Company’s Current Report on Form 8-K filed on July 13, 2021 3.4 Corporate Bylaws Incorporated by reference from the Company’s Registration Statement on Form SB-2 (File No. 333-68008) filed with the SEC on August 20, 2001. 3.5 Amendment No. 1 to the Bylaws of PharmaCyte Biotech, Inc. Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on September 25, 2014. 3.6 Amendment No. 2 to the Bylaws of PharmaCyte Biotech, Inc. Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on October 3, 2014. 3.7 Amendment No. 3 to PharmaCyte’s Bylaws, as previously filed as Exhibit 99.2 to the Company’s Current Report on Form 8-K on June 4, 2021 Incorporated by reference from the Company’s Current Report on Form 10-K filed on August 10, 2021 3.8 Amendment No. 4 to PharmaCyte’s Bylaws, as previously filed as Exhibit 99.2 to the Company’s Current Report on Form 8-K on July 6, 2021 Incorporated by reference from the Company’s Current Report on Form 10-K filed on August 10, 2021 3.9 Form of Common Warrant Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on August 12, 2021. 3.10 Form of Pre-Funded Warrant Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on August 12, 2021. 3.11 Form of Underwriter’s Warrant Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on August 12, 2021. 38 4.1 Form of Pre-Funded Common Stock Purchase Warrant Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on August 23, 2021. 4.2 Form of Series A Purchase Warrant Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on August 23, 2021. 4.3 Form of Placement Agent Common Stock Purchase Warrant Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on August 23, 2021. 4.4 Securities Purchase Agreement, dated as of August 19, 2021 Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on August 23, 2021. 31.1 Principal Executive Officer Certification required by Rules 13a-14 and 15d-14as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith 31.2 Principal Executive Officer Certification required by Rules 13a-14 and 15d-14as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith 32.1 Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002 Furnished herewith 32.2 Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002 Furnished herewith 101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101). 39 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized. PharmaCyte Biotech, Inc. December 14, 2021 By: /s/ Kenneth L. Waggoner Kenneth L. Waggoner Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer) December 14, 2021 By: /s/ Carlos A. Trujillo Carlos A. Trujillo Chief Financial Officer (Duly Authorized Officer and Principal Financial and Principal Accounting Officer) 40